NetworkNewsBreaks

MondayJun 29, 2026 10:05 am

NetworkNewsBreaks – Swarmer, Inc. (NASDAQ: SWMR) Expands European Software Contract, Adds $1.02 Million in Expected Revenue

Swarmer (NASDAQ: SWMR) announced an amendment to its May 2026 software licensing agreement that increases the total contract value to $3.87 million and is expected to generate an additional $1.02 million in revenue. Under the revised agreement, Czech-based Progress TRW S.R.O. will purchase $1.41 million in SkyKnight software licenses, while Meta Bureau LLC increased its original autonomy software order from $1.38 million to $2.47 million. If all contract options are exercised by Meta Bureau and Progress TRW, the agreement could reach a total value of $14.20 million. The licenses cover Swarmer's software platform, including its operating system, artificial intelligence and…

Continue Reading

MondayJun 29, 2026 9:40 am

NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) reported fiscal 2026 financial results and provided an update on its clinical pipeline, highlighting continued progress of its lead candidate HLP003 for major depressive disorder. The company said its Phase 3 APPROACH trial has surpassed 88% enrollment and remains on track to deliver topline data in the fourth quarter of 2026, while enrollment continues in the second pivotal Phase 3 EMBRACE study. Helus also said it expects to finalize the design of the next clinical study for HLP004…

Continue Reading

MondayJun 29, 2026 9:30 am

NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Enrolls First Patient in Phase 2 Depression Trial

Tonix Pharmaceuticals (NASDAQ: TNXP) announced the first patient has been enrolled in the HORIZON Phase 2 trial evaluating TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study is expected to enroll approximately 360 patients at about 30 U.S. sites and will assess changes in depression severity after six weeks of treatment, along with measures of sleep quality, anxiety and global clinical improvement. TNX-102 SL is designed to improve sleep quality, which the company believes plays an important role in MDD, and is already approved by the FDA under the…

Continue Reading

MondayJun 29, 2026 9:20 am

NetworkNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches AI Agent Platform for Patient Scheduling and Care Coordination

HealthLynked (OTCQB: HLYK) announced the launch of its next-generation AI Agent Platform, a conversational voice AI solution designed to automate patient scheduling, care coordination and healthcare communications for both patients and providers. The platform supports inbound and outbound voice interactions, enabling AI agents to schedule appointments, navigate physician office phone systems, collect patient and insurance information, perform intake functions, confirm appointments and provide 24/7 answering services for healthcare practices. The company said the platform is designed to help physician practices, accountable care organizations, health systems and insurers improve patient access while reducing administrative burdens and staffing requirements. HealthLynked plans a…

Continue Reading

MondayJun 29, 2026 9:10 am

NetworkNewsBreaks – Xlife Sciences AG (SIX: XLS) Shareholders Approve All Annual Meeting Proposals

Xlife Sciences (SIX: XLS) announced that shareholders approved all proposals presented at the company's Annual General Meeting, where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. Chairman David L. Deck said the company strengthened its portfolio during the past year and highlighted the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform as key milestones supporting the next phase of growth. The company also emphasized the strategic importance of the planned Landsteiner Scientific platform, which is intended to accelerate the identification and development of novel therapeutic approaches while improving global…

Continue Reading

MondayJun 29, 2026 9:00 am

NetworkNewsBreaks – Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) Signs Agreement to Acquire Quantum.IQ

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising. Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) has entered into a definitive share purchase agreement to acquire Vancouver-based Quantum.IQ Technologies Inc., expanding its technology platform into quantum-resistant cybersecurity, cryptographic intelligence and enterprise security infrastructure modernization. The acquisition is expected to broaden Redwood's exposure beyond AI and operational intelligence into post-quantum cybersecurity, enterprise resilience and critical infrastructure modernization, subject to customary closing conditions and regulatory approvals. Under the agreement, Redwood will issue up to 14,033,558 common shares valued at approximately $2.98 per share,…

Continue Reading

FridayJun 26, 2026 2:57 pm

NetworkNewsBreaks – CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Focuses on Long-Term Opportunity as Market Dynamics Evolve

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising. CMX (CSE: CXC) (OTC: CXXMF) is an exploration-stage company advancing the wholly owned Clayton Silver Project in Idaho. The company was featured in a recent article that discussed its positioning to navigate increasing volatility in precious metals markets driven in part by the growing influence of derivatives trading. While derivatives can improve liquidity and provide hedging opportunities, they can also contribute to heightened leverage and skewed prices. Against this backdrop, the company remains focused on advancing its historic Clayton Silver Mine, which it believes could…

Continue Reading

FridayJun 26, 2026 2:18 pm

NetworkNewsBreaks – AMC Entertainment Holdings, Inc. (NYSE: AMC) Closes $200 Million Registered Direct Offering 

AMC (NYSE: AMC) announced the closing of its previously announced registered direct offering of 95.25 million shares of common stock, generating approximately $200 million in gross proceeds before fees and expenses. The company said it intends to use the proceeds primarily to redeem all $125.47 million of its 6.125% Senior Subordinated Notes due 2027, eliminating any anticipated material debt principal repayments before 2029. The company said the remaining proceeds will support general corporate purposes, strengthen its cash reserves and fund targeted investments in seating upgrades and premium screens at selected higher-grossing theaters. AMC said the debt repayment is expected to reduce annual cash interest expense by approximately $7.7 million…

Continue Reading

FridayJun 26, 2026 2:12 pm

NetworkNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Analytics Beyond Traditional Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection. The company was featured in a recent article that discussed its efforts to broaden the scope of its platform with the development of a fatigue prediction model designed for high-risk workplace environments. “The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of alcohol, drug impairment and fatigue from short voice…

Continue Reading

FridayJun 26, 2026 11:46 am

NetworkNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification

BioAdaptives (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status, confirming compliance with anti-doping standards established by the World Anti-Doping Agency and the UFC. Combined with the previously certified MyndMed(TM) daytime formula, the company said MyndSystem(TM) is now a fully WADA-compliant 24/7 cognitive performance and recovery system for professional athletes. The company said the certification strengthens its position in the sports nutrition market by supporting potential adoption among professional athletes while also targeting executives and active seniors. BioAdaptives said the milestone could enhance commercialization opportunities, strategic partnerships and broader market adoption as it expands the MyndSystem(TM) platform. To view the full press release, visit https://nnw.fm/Gs2IX About BioAdaptives, Inc. BioAdaptives,…

Continue Reading